STOP AF 承認後最初の試験
STOP AF 最初の承認後試験、Cryo Global Registry の補遺
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
調査の概要
詳細な説明
The STOP AF First Post Approval Study (PAS) is a sub-study to the Cryo Global Registry. The STOP AF First PAS is a prospective, global, multi-center, observational trial. The purpose of the study is to describe long-term clinical performance and safety data in the recurrent symptomatic paroxysmal AF population treated with Arctic Front™ and Freezor™ MAX Families of cardiac cryoablation catheters (hereafter referred to as Arctic Front™ Cardiac Cryoablation Catheter System) as an alternative to antiarrhythmic drug therapy as an initial rhythm control strategy. This PAS is a condition of the pre-market approval order (P100010/S110) by the U.S. Food and Drug Administration.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Alaska
-
Anchorage、Alaska、アメリカ、99508
- Alaska Heart Institute
-
-
Connecticut
-
Stamford、Connecticut、アメリカ、06905-5522
- Cardiology Associates of Fairfield County
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- MedStar Washington Hospital Center
-
-
Florida
-
Clearwater、Florida、アメリカ、33756
- BayCare Medical Group Cardiology
-
Davie、Florida、アメリカ、33328
- Heart Rhythm Solutions
-
-
Iowa
-
West Des Moines、Iowa、アメリカ、50266
- Iowa Heart
-
-
Massachusetts
-
North Dartmouth、Massachusetts、アメリカ、02747
- Southcoast Health System
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202-2608
- Henry Ford Heart & Vascular
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- The Lindner Research Center
-
-
Tennessee
-
Germantown、Tennessee、アメリカ、38138
- Stern Cardiovascular Foundation
-
-
Texas
-
Dallas、Texas、アメリカ、75231
- Texas Health Research and Education Institute
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Subjects ≥ 18 years of age (or minimum age as required by local regulations) who have a recommendation for a pulmonary vein ablation with the Arctic Front™ cardiac cryoablation catheter System.
説明
Inclusion Criteria:
- Subject has been diagnosed with symptomatic paroxysmal AF
- Subject is ≥ 18 years of age or minimum age as required by local regulations
- Planned pulmonary vein isolation (PVI) procedure using the commercially available Arctic Front™ cardiac cryoablation catheter System.
- Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements
Exclusion Criteria:
History of AF treatment with a class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence1
. Subjects under the following conditions may be included in the study:
-
Temporary treatment with a class I or III AAD (treatment at a therapeutic dose for a period of <4 weeks prior to the index PVI procedure)
-
Recent treatment with a class I or III AAD (within 6 months of the index PVI procedure) at a dose below therapeutic threshold according to the AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation
-
A subject who has received a chemical cardioversion may be included in the study. This includes a chemical cardioversion prior to enrollment and between enrollment and ablation.
- Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL)
- Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager
- Subject with exclusion criteria required by local law
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Freedom from Atrial Fibrillation (AF) /Atrial Flutter (AFL) /Atrial Tachycardia (AT)
時間枠:36 months
|
Estimate the 36-month freedom from Atrial Fibrillation (AF) /atrial flutter (AFL) /Atrial Tachycardia (AT) recurrence using the Arctic Front™ cardiac cryoablation catheter System. |
36 months
|
|
Freedom from Primary Safety Events
時間枠:12 months
|
Estimate primary safety Adverse Event (AE) rates for cryoablation using the Arctic Front™ cardiac cryoablation catheter System through 12-months. |
12 months
|
協力者と研究者
捜査官
- スタディディレクター:Khaldoun Tarakji, MD、Medtronic CAS Chief Medical Officer
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。